Drug Insights

Explore Levofloxacin on Synapse: Tips and Tricks for Better Search Results

4 March 2024
2 min read

Levofloxacin is an effective synthetic antibacterial agent used for treating different types of bacterial infections such as respiratory, urinary tract, skin and soft tissue, and bacterial prostatitis. It belongs to the fluoroquinolones class of antibiotics and prevents the DNA replication process in bacteria, eventually leading to cell death. Levaquin is one of the popular brand names for this drug, available in oral, intravenous, and eye drop forms.Due to its broad-spectrum activity, Levofloxacin is effective against both Gram-positive and Gram-negative bacteria, including those that are resistant to other antibiotics. This feature makes it a valuable option in treating serious infections caused by multidrug-resistant bacteria.Levofloxacin was patented in 1985 and approved by the US Food and Drug Administration by JANSSEN PHARMS in 1996. Since then, it has been widely used and considered as an important therapeutic option in the treatment of different bacterial infections. Click on the image below to begin the exploration journey of Levofloxacin through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Authorizes ARTHEx for Early ATX-01 Trial in Myotonic Dystrophy under ArthemiR™
Latest Hotspot
3 min read
FDA Authorizes ARTHEx for Early ATX-01 Trial in Myotonic Dystrophy under ArthemiR™
4 March 2024
FDA Grants ARTHEx Biotech Authorization to Start Early-Stage Clinical Study for ATX-01 in Treating Myotonic Dystrophy (DM1) under the ArthemiR™ Project.
Read →
Harnessing Synapse for Sumatriptan Information: Strategies and Tips
Drug Insights
2 min read
Harnessing Synapse for Sumatriptan Information: Strategies and Tips
4 March 2024
Sumatriptan is a small molecule drug and developed by GSK. Its first approved in 1996 in the USA.
Read →
Ironwood Pharma Reports Positive Phase III Results for Apraglutide in Adult Short Bowel Syndrome
Latest Hotspot
3 min read
Ironwood Pharma Reports Positive Phase III Results for Apraglutide in Adult Short Bowel Syndrome
4 March 2024
Ironwood Pharma reveals encouraging initial findings from an international Phase III study of Apraglutide, a weekly treatment for Short Bowel Syndrome leading to Intestinal Failure in adults.
Read →
Effortless Searching: How to Find Modafinil on Synapse
Drug Insights
2 min read
Effortless Searching: How to Find Modafinil on Synapse
4 March 2024
Modafinil, a minuscule molecular compound marketed as PROVIGIL, received its initial approval in 1992.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.